apatinib also known rivoceranib tyrosine kinase inhibitor selectively inhibits vascular endothelial growth factor also known kdr orally bioavailable small molecule agent thought inhibit angiogenesis cancer cells specifically apatinib inhibits vegfmediated endothelial cell migration proliferation thus blocking new blood vessel formation tumor tissue agent also mildly inhibits ckit csrc tyrosine apatinib first synthesized advenchen laboratories california usa licensed global rights hlb korea developed jiangsu hengrui medicine china lsk biopartners us hlb life science investigational cancer drug currently undergoing clinical trials potential targeted treatment metastatic gastric carcinoma metastatic breast cancer adenoid cystic carcinoma advanced hepatocellular carcinoma principal investigator fudan university china presented results phase iii human clinical studies csco meeting october cancer patients administered varied doses apatinib daily days apatinib well tolerated doses mgday doselimiting toxicities reported mgday maximum tolerated dose determined mgday investigator also reported cancer patients treated phase iii complete response partial response stable disease progressive separate published report safety pharmacokinetics apatinib human clinical studies concludes encouraging antitumor activity across broad range cancer phase iiiii study recruiting patients china determine whether apatinib improve progressionfree survival compared placebo patients metastatic gastric carcinoma failed two lines chemotherapy september apatinib approved cfda december patients latestage gastric carcinoma phase iv study safety apatinib started april study aims recruit november two additional phase ii clinical studies initiated apatinib metastatic triplenegative breast cancer patients advanced hepatocellular march bukwang announced filed ind korean fda begin human clinical studies apatinib phase august bukwang licensed commercial rights korea rivoceranib hlb life science cancer cells ability develop resistance cytotoxic effects certain cancer drugs called multidrug resistance study concluded apatinib may useful circumventing cancer cells multidrug resistance certain conventional antineoplastic study showed apatinib reverses multidrug resistance inhibiting functions increasing intracellular concentrations antineoplastic drugs study suggests apatinib potentially effective combination therapies conventional anticancer drugs especially cases resistance chemotherapy existscitation needed httpsenwikipediaorgwikiapatinib